13F-HR filed by Omega Fund Management, LLC
Omega Fund Management, LLC filed this 13F-HR for the quarter ended 2022-12-31, filed 2023-02-13, with 16 holding rows worth $296,715,662.
- Accession
- 0000950123-23-002007
- Filer
- CIK 1637359
- Filed
- 2023-02-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2022
A holdings report, 16 entries on the cover page, a total value of $296,715,662 stated on the cover page (in dollars after the unit check, H1), rows summing to $296,715,662 with VALUE read as dollars as filed, 13F file number 028-16844. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| IMAGO BIOSCIENCES INC | 45250K107 | COM | 3,018,737 | $108,523,595 | dollars as filed | |
| REPLIMUNE GROUP INC | 76029N106 | COMMON STOCK | 3,361,806 | $91,441,123 | dollars as filed | |
| NUVATION BIO INC COM CL A | 67080N101 | Stock | 15,072,340 | $28,938,893 | dollars as filed | |
| MORPHIC HLDG INC | 61775R105 | COM | 597,723 | $15,989,090 | dollars as filed | |
| ALPINE IMMUNE SCIENCES INC | 02083G100 | COM | 2,029,580 | $14,917,413 | dollars as filed | |
| CINCOR PHARMA INC | 17240Y109 | COM | 560,985 | $7,853,790 | dollars as filed | |
| KRONOS BIO INC | 50107A104 | COM | 3,818,283 | $6,185,619 | dollars as filed | |
| IKENA ONCOLOGY INC | 45175G108 | COM | 2,249,123 | $5,982,667 | dollars as filed | |
| PARATEK PHARMACEUTICALS INC | 699374302 | Equity | 1,971,241 | $3,686,221 | dollars as filed | |
| THESEUS PHARMACEUTICALS INC | 88369M101 | COM | 711,479 | $3,543,165 | dollars as filed | |
| SANA BIOTECHNOLOGY INC | 799566104 | COM | 843,750 | $3,332,813 | dollars as filed | |
| IMMUNIC INC | 4525EP101 | COM | 1,788,160 | $2,503,424 | dollars as filed | |
| SPRUCE BIOSCIENCES INC | 85209E109 | COM | 2,161,022 | $2,333,904 | dollars as filed | |
| SYROS PHARMACEUTICALS INC | 87184Q206 | COM NEW | 251,270 | $902,059 | dollars as filed | |
| JOUNCE THERAPEUTICS INC | 481116101 | COM | 275,513 | $305,819 | dollars as filed | |
| Senti Biosciences, Inc. | 81726A100 | Common Stock | 195,792 | $276,067 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-23-002007 | this filing | 2023-02-13 | acceptance time not in the bulk data set |